Initial studies evaluating ISO-1 as a therapeutic agent for endometriosis treatment are encouraging as the MIF antagonist reduces lesion burden in mouse models which harbor both mouse and human tissue, demonstrating efficacy. The gene discussed is MIF; the disease is endometriosis.